Table: Ono Pharm -2023/24 group results (IFRS)
May 9 (Reuters)-
Ono Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2024 Mar 31, 2023 Mar 31, 2025 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 502.67 447.19
(+12.4 pct) (+23.8 pct)
Sales 450.00
(-10.5 pct)
Operating 159.94 141.96 122.00
(+12.7 pct) (+37.6 pct) (-23.7 pct)
Pretax 163.73 143.53 123.00
(+14.1 pct) (+36.7 pct) (-24.9 pct)
Net 127.98 112.72 91.00
(+13.5 pct) (+40.0 pct) (-28.9 pct)
EPS Basic 266.61 yen 230.85 yen 193.76 yen
EPS Diluted 266.57 yen 230.79 yen
Ann Div 80.00 yen 70.00 yen 80.00 yen
-Q2 Div 40.00 yen 33.00 yen 40.00 yen
-Q4 Div 40.00 yen 37.00 yen 40.00 yen
NOTE - Ono Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4528.T
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours